for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DBV Technologies SA

DBV.PA

Latest Trade

14.39EUR

Change

-0.01(-0.07%)

Volume

176,946

Today's Range

14.00

 - 

14.69

52 Week Range

7.59

 - 

34.82

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
14.40
Open
14.69
Volume
176,946
3M AVG Volume
5.55
Today's High
14.69
Today's Low
14.00
52 Week High
34.82
52 Week Low
7.59
Shares Out (MIL)
36.12
Market Cap (MIL)
677.21
Forward P/E
-3.10
Dividend (Yield %)
--

Next Event

Q3 2019 DBV Technologies SA Corporate Sales Release

Latest Developments

More

DBV Announces Pricing Of 125 Million Dollars Global Offering Of Ordinary Shares

Dbv Technologies Announces FDA Acceptance Of BLA Filing For Viaskin Peanut

DBV Technologies Announces FDA Acceptance Of BLA Filing For Viaskin Peanut

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DBV Technologies SA

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Industry

Biotechnology & Drugs

Contact Info

177-181 avenue Pierre Brossolette

+33.1.55427878

https://www.dbv-technologies.com/

Executive Leadership

Michel de Rosen

Non-Executive Chairman of the Board

Daniel Tasse

Chief Executive Officer, Director

Joan Schmidt

Executive Vice President, General Counsel

Hugh A. Sampson

Chief Scientific Officer

Pharis Mohideen

Chief Medical Officer

Key Stats

1.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-4.680

2017

-5.970

2018

-5.740

2019(E)

-4.649
Price To Earnings (TTM)
--
Price To Sales (TTM)
47.30
Price To Book (MRQ)
4.47
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
20.80
LT Debt To Equity (MRQ)
18.09
Return on Investment (TTM)
-97.59
Return on Equity (TTM)
-79.56

Latest News

Latest News

BRIEF-DBV Technologies: Potential Long-Term Benefit Of Viaskin Peanut

* ANNOUNCED ON SATURDAY THE COMPANY WILL PRESENT DATA FROM EPICUTANEOUS IMMUNOTHERAPY AT EAACI 2019

BRIEF-DBV Technologies FY Net Loss Widens To 166.1 Million Euros

* REPORTED ON TUESDAY FY SALES AND MARKETING EXPENSES EUR 32.2 MLN VS EUR 15.8 MLN YR AGO

BRIEF-DBV Technologies To Resubmit Biologics License Application For Viaskin Peanut In Q3 2019

* ANNOUNCED ON WEDNESDAY UPDATE ON REGULATORY STATUS OF VIASKIN PEANUT FOR THE TREATMENT OF PEANUT-ALLERGIC CHILDREN 4 TO 11 YEARS OF AGE

BRIEF-DBV Technologies Reports Cash position of 234.5 Million Euros at end March

* CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018, WERE EUR 234.5 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DBV Technologies: Closing Of Underwriters' Option To Purchase Additional Shares In Global Offering

* REG-DBV TECHNOLOGIES ANNOUNCES CLOSING OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES IN GLOBAL OFFERING

BRIEF-DBV Technologies Announces Pricing Of 122.5 Million Euros Global Offering Of Ordinary Shares

* ANNOUNCES PRICING OF $150.0 MILLION (EUR 122.5 MILLION) GLOBAL OFFERING OF ORDINARY SHARES

BRIEF-DBV Technologies ‍Announces Intention To Issue And Sell Up To $150 Mln Of New Ordinary Shares​

* DBV TECHNOLOGIES ANNOUNCES THE LAUNCH OF A PROPOSED GLOBAL OFFERING OF ORDINARY SHARES, WHICH MAY BE IN THE FORM OF AMERICAN DEPOSITARY SHARES

BRIEF-DBV Technologies FY Net Loss widens to 147.7 Million Euros

* CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017 EUR 137.9 MILLION VERSUS EUR 256.5 MILLION YEAR AGO

BRIEF-DBV Technologies Announces Result From Phase II Study of Viaskin Milk

* ANNOUNCED ON MONDAY, RESULT FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

BRIEF-DBV Technologies Announces Results From Phase II Study Of Viaskin Milk In Milk-Allergic Patients

* DBV TECHNOLOGIES ANNOUNCES RESULTS FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

BRIEF-DBV Technologies Cash And Cash Equivalents At Dec. 31 Down At 137.9 Million Euros

* CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017, WERE EUR 137.9 MILLION, VERSUS EUR 256.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Reg-Dbv Technologies Provides Update On Regulatory Progress For Viaskin Peanut

* REG-DBV TECHNOLOGIES PROVIDES UPDATE ON REGULATORY PROGRESS FOR VIASKIN PEANUT

BRIEF-DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​

* ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT

BRIEF-DBV Technologies reports at Sept. 30 cash position of 170.5 million euros

* CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 Source text: http://bit.ly/2htbI61 Further company coverage: (Gdynia Newsroom)

BRIEF-DBV Technologies ‍cash position of 170.5 million euros as of September 30​

* CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2017, WERE EUR 170.5 MILLION, COMPARED TO EUR 256.5 MILLION AS OF DECEMBER 31, 2016 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study

* DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age

DBV Technologies peanut allergy drug fails key study

DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.

DBV Technologies peanut allergy drug fails key study

Drug developer DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study.

BRIEF-DBV Technologies completes blinded period in REALISE study of Viaskin Peanut

* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF BLINDED PERIOD IN REALISE STUDY OF VIASKIN PEANUT

BRIEF-DBV Technologies completes enrollment in Phase III extension study of Viaskin Peanut

* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE III EXTENSION STUDY OF VIASKIN PEANUT

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up